Tumor Acidity and Near‐Infrared Light Responsive Dual Drug Delivery Polydopamine‐Based Nanoparticles for Chemo‐Photothermal Therapy
Source abstract
Abstract
Abstract Photothermal therapy (PTT) combined with chemotherapy, a promising strategy for breast cancer treatment, has a high potential to control drug release, reduce multidrug resistance, and improve therapeutic efficacy. The challenge is how to realize tumor ablation in deeper tissue and NIR‐controlled drug delivery. Herein, tumor acidity and near‐infrared light (NIR) responsive folic acid (FA) functionalized polydopamine (DPA) nanoparticles (NPs) are developed for doxorubicin (DOX) and epigallocatechin‐3‐gallate (EGCG) dual delivery. With the assistance of NIR, the cellular uptake of DOX‐EGCG/DPA‐FA NPs is about three‐ to sixfold higher when compared with the free DOX group and the control group without NIR irradiation. Moreover, biodistribution study in vivo indicates that DPA‐FA NPs can enhance tumoral accumulation, penetration, retention of drugs, and display a ≈4‐ and 19‐fold higher intra‐tumoral distribution than that of the DPA NPs and free drug groups at 24 h postinjection. Furthermore, 60% of breast cancer‐bearing mice survive over 70 days in the DOX‐EGCG/DPA‐FA NPs group. Additionally, DOX‐EGCG/DPA‐FA NPs can effectively boost therapeutic efficacy by inducing significant suppression of tumor growth and angiogenesis, and enhancement of apoptosis and necrosis of breast cancer cells. Taken together, DOX‐EGCG/DPA‐FA NPs may have potential applications as a useful nanoscale vector for enhanced cancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Neurosurgery West China Hospital Sichuan University Chengdu 610041 P. R. China
State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University and Collaborative Innovation Center for Biotherapy Chengdu 610041 P. R. China
School of Basic Medical Sciences Xinxiang Medical University Xinxiang Henan 453003 P. R. China
References (55)
Show source-provided references
1. 10.7150/thno.2407310.7150/thno.24073 ↗
2. 10.1038/s41467-020-14780-510.1038/s41467-020-14780-5 ↗
3. 10.2147/IJN.S21437710.2147/IJN.S214377 ↗
4. 10.1002/cncr.3202210.1002/cncr.32022 ↗
5. 10.1126/sciadv.abc873310.1126/sciadv.abc8733 ↗
6. 10.1016/j.msec.2019.11010310.1016/j.msec.2019.110103 ↗
7. 10.1021/acsami.9b0585510.1021/acsami.9b05855 ↗
8. 10.1021/acs.nanolett.9b0212710.1021/acs.nanolett.9b02127 ↗
9. 10.1002/adfm.20190886510.1002/adfm.201908865 ↗
10. 10.1016/j.biomaterials.2016.10.05310.1016/j.biomaterials.2016.10.053 ↗
11. 10.1021/acsnano.9b0009710.1021/acsnano.9b00097 ↗
12. 10.1016/j.apmt.2018.11.00810.1016/j.apmt.2018.11.008 ↗
13. 10.1016/j.cclet.2018.03.01910.1016/j.cclet.2018.03.019 ↗
14. 10.1016/j.biomaterials.2020.11997610.1016/j.biomaterials.2020.119976 ↗
15. 10.1002/adfm.20200105910.1002/adfm.202001059 ↗
16. 10.1007/s12551-019-00532-310.1007/s12551-019-00532-3 ↗
17. 10.2147/IJN.S22279710.2147/IJN.S222797 ↗
18. 10.1021/acs.biomac.9b0060010.1021/acs.biomac.9b00600 ↗
19. 10.1021/acsami.9b0047210.1021/acsami.9b00472 ↗
20. 10.1016/j.jconrel.2019.07.03610.1016/j.jconrel.2019.07.036 ↗
21. 10.1002/adma.20120468310.1002/adma.201204683 ↗
22. Wang S. · Adv. Ther. · 2020 · 11
23. 10.1166/jbn.2019.280610.1166/jbn.2019.2806 ↗
24. 10.1016/j.actbio.2016.10.01010.1016/j.actbio.2016.10.010 ↗
25. 10.1016/j.bioactmat.2020.04.00310.1016/j.bioactmat.2020.04.003 ↗
26. 10.1016/j.cej.2019.12346310.1016/j.cej.2019.123463 ↗
27. 10.1016/j.bcp.2015.02.00610.1016/j.bcp.2015.02.006 ↗
28. 10.1016/j.lfs.2016.12.00410.1016/j.lfs.2016.12.004 ↗
29. 10.7150/thno.1513310.7150/thno.15133 ↗
30. 10.1021/acsami.5b0561810.1021/acsami.5b05618 ↗
31. 10.1016/j.bbrc.2018.07.10510.1016/j.bbrc.2018.07.105 ↗
32. 10.1016/j.cej.2020.12620010.1016/j.cej.2020.126200 ↗
33. 10.1016/j.clnu.2013.03.00810.1016/j.clnu.2013.03.008 ↗
34. 10.1016/j.canlet.2008.04.01410.1016/j.canlet.2008.04.014 ↗
35. 10.1002/cncr.2490610.1002/cncr.24906 ↗
36. 10.1039/C9BM01614G10.1039/C9BM01614G ↗
37. 10.1021/acsami.8b2148310.1021/acsami.8b21483 ↗
38. 10.1016/j.bmcl.2014.03.08810.1016/j.bmcl.2014.03.088 ↗
39. 10.1016/j.ejps.2020.10548710.1016/j.ejps.2020.105487 ↗
40. 10.1021/acsami.8b0865910.1021/acsami.8b08659 ↗
41. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
42. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
43. 10.1021/acsnano.0c0282110.1021/acsnano.0c02821 ↗
44. 10.1038/s41467-020-16838-w10.1038/s41467-020-16838-w ↗
45. 10.1038/s41571-020-0339-510.1038/s41571-020-0339-5 ↗
46. 10.1021/acsami.0c0518910.1021/acsami.0c05189 ↗
47. 10.1021/acsami.8b0479910.1021/acsami.8b04799 ↗
48. 10.1002/adma.20170696310.1002/adma.201706963 ↗
49. 10.1016/j.biomaterials.2015.11.03710.1016/j.biomaterials.2015.11.037 ↗
50. 10.7150/thno.3676210.7150/thno.36762 ↗
51. 10.1039/C9BM01646E10.1039/C9BM01646E ↗
52. 10.1039/C9NR01320B10.1039/C9NR01320B ↗
53. 10.1002/adma.20170358810.1002/adma.201703588 ↗
54. 10.1002/advs.20160028510.1002/advs.201600285 ↗
55. 10.1016/j.cclet.2018.02.01510.1016/j.cclet.2018.02.015 ↗